Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSLP Vaccine in Local or Metastatic Solid Tumors
NCT05741242Phase 2Enrolling by invitation
- Sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NeoSLP in solid tumor, pancreatic adenocarcinoma (PDAC) and glioblastoma (GBM), sponsored by Jaime Leandro Foundation for Therapeutic Cancer Vaccines. Primary endpoint: Progression-Free Survival at 12 months. Started Nov 2022; status: enrolling by invitation.
02
Drugs
NeoSLP
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05741242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741242.